ESR1 and breast carcinoma: Previous studies demonstrated that cross talks between the signaling pathways of estrogen receptor (ER) and IGF-1 receptor (R) play a crucial role in determining resistance to anti-estrogen endocrine therapy in breast cancer [19–21].